Pioneering in development
of Immuno-oncology vaccines

Our Company based on 3 core elements of cancer vaccine development: (1) novel adjuvants; (2) neo-antigens discovery,  and (3) innovative delivery platforms. AilseVax is developing innovations across all three domains to develop the next generation of cancer vaccines.

Founded by cancer biologists, immunologists, data scientists and an experienced management team with excellent track-record in building multiple successful life sciences ventures.

Our Team

AilseVax scientists have world-recognized expertise in functional genomics, drug delivery and vaccine adjuvants. Our team consists of scientists and advisors with extensive experience in cancer biology, neo-antigen discovery, vaccine adjuvants, IND-enabling studies, and early phase clinical trials.

Located in Belfast, AilseVax formed as a spin out company from Trinity College Dublin and Queen’s University Belfast; two of the leading research universities on the island of Ireland.


Our science is based on the development of advanced antigen formulations that bring together adjuvant and delivery innovations to enhance antigen presentation and promote anti-tumour immune responses.

In cancer, adjuvants are designed to promote an anti-tumor immune response.
C100™ is our chitin-derived adjuvant technology that has demonstrated great potential for enhancing anti-tumor immunity.

AltRNAV8™ antigen discovery engine
AilseVax has developed the AltRNA8V™ antigen discovery engine to exploit the untapped wealth of antigenic potential encoded in abnormal RNAs and their translation products.

Our unique combination of cutting-edge genomics methods, datasets and analysis workflows enable identification of cancer-specific antigens that are not detected by the existing methods. We believe this will enable the creation of new vaccines for the treatment and prevention of cancer

AilseVax Adjuvant Technologies
Novel vaccine adjuvants are required to promote cellular immunity for cancer vaccines. C100™ is our chitin-derived adjuvant technology that demonstrates efficacy in promoting protective cell-mediated immunity in a therapeutic setting.  Our second adjuvant technology based on biodegradable nanoparticles promotes antigen specific CD4 and CD8 responses to purified proteins.

Our pipeline

FOCUSING ON CANCER Vaccines that work in multiple patient populations

AilseVax’s goal is to use our proprietary technology platforms to develop cancer vaccines that work in multiple patient populations

Clinical Indications
Head & Neck, Prostate
Phase I
Clinical Indications
Phase I

Latest Events & Press Releases

BIO 2022 Convention, San Diego, CA USA
Don't miss the opportunity to meet our team. We look forward to seeing you in San Diego


AilseVax recognises the value of collaborating with external experts to develop our science into novel treatments that will positively impact the treatment of cancer.

We welcome enquiries about establishing new partnerships and collaborations, including joint efforts to expand our AltRNAV8™ antigen discovery engine and our Adjuvant platforms to enable the development of new immunotherapies in multiple types of cancer.

If you are interested in partnering with us, please contact us (link). AilseVax has established partnerships with the following leading academic institutes and companies to support our scientific innovation and development strategies. Click on the icons below for more information.